Optimal Management of Histone Deacetylase Inhibitor –Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat

Recent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges given the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to use new therapeutic agents optimally. Panobinostat is the first histone deacetylase inhibitor approved for the treatment of multiple myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research